Biosimilars and Access to Treatment [1]

Biosimilars can expand patient access to life-changing biologic medicines[1], and may offer significant savings for patients, helping alleviate the overburdened healthcare system.[2,3]

- As more biosimilars enter the US market, patients treated with biologic medicines will have access to a broader set of more affordable treatment options.[4]
- Annual cost savings from biosimilar medicines reached $6.5 billion in 2020.[5] These savings can be used to treat more patients and have the potential to save the US healthcare system $100 billion over 5 years.[6]
- The potential savings created by biosimilars through increased competition would help healthcare systems reallocate resources to meet the challenge of caring for a growing aging population.[7,8]
- An estimated 1.2 million US patients could gain access to biologics by 2025 as the result of increasing biosimilar availability.[4]

As a global leader in biosimilars and the first to bring a biosimilar medicine to the US, Sandoz is working to improve patient access to more affordable, high-quality, potentially life-changing biologic treatments.[9]

- Sandoz has contributed more than 530 million patient-experience days with our biosimilars in almost 100 countries.[10,11]
- With four FDA-approved biosimilars and a strong pipeline, Sandoz is well-positioned to lead the US biosimilars industry in development, manufacturing and commercialization.
- Sandoz has the first proven biosimilar success story in the US with demonstrated cost savings and the potential to expand patient access.[12,13] Sandoz is committed to working with all stakeholders to address barriers impacting biosimilar adoption and continues to pioneer access for patients.
- By actively investing in the future of biosimilars, Sandoz continues to lead the marketplace and deliver on our purpose to help millions of patients in immunology, oncology, endocrinology and other underserved therapy areas to access biologic medicines sustainably and affordably.

Go to Biosimilar Development Process > [2]

References: 1. Data on file. Zarxio Market Share Analysis. Sandoz Inc. January 2019. 2. IQVIA Institute for Human Data Science. Medicine use and spending in the US: a review of 2017 and outlook to 2022. https://www.iqvia.com/institute/reports/medicine-use-and-spending-in-the... [3]. Accessed October 7, 2020. 3. U.S. Food and Drug Administration. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA's Biosimilar Action Plan [press release]. July 18, 2018. 4. The Biosimilars Council. Biosimilars in the United States: Providing More Patients Greater Access to Lifesaving Medicines. Available at: http://biosimilarscouncil.org/wp-content/uploads/2019/03/Biosimilars-Cou... [4]. Accessed on October 7, 2020. 5. Fein, AJ. Drug Channels. The Booming Biosimilar Market of 2020. Published October 6, 2020. https://www.drugchannels.net/2020/10/the-booming-biosimilar-market-of-20... [5]. Accessed October 7, 2020. 6. IQVIA Institute for Human Data Science. Biosimilars in the United States 2020–2024. Published October 6, 2020. Accessed October 7, 2020. 7. Ortman J, Velkoff V, Hogan H. An aging nation: the older population in the United States. US Census Bureau. Issued May 2014. https://www.census.gov/prod/2014pubs/p25-1140.pdf [6]. Accessed October 7, 2020. 8. Mulcahy AW, Hlávka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Santa Monica, CA: Rand Corporation, 2017. https://www.rand.org/pubs/perspectives/PE264.html [7]. 9. US Food and Drug Administration. FDA approves first biosimilar product Zarxio [press release]; March 6, 2015. https://wayback.archive [8] it.org/7993/20170111224313/ http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm [9]. Accessed April 17, 2020. 10. Data on file. Periodic Safety Update Reports. Sandoz Inc. 11. Data on file. Sandoz Inc. February 2020. 12. Data on file. Sandoz ZARXIO wholesale acquisition cost (WAC) Data June 2018 Resource. Sandoz Inc. June 2018. 13. McBride A, Balu S, Campbell K, Bikkina M, MacDonald K, Abraham I. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastimsndz. Future Oncol. 2017;13(25):2285–2295. doi:10.2217/fon-2017-0374.

Accordion Type:

- Collapsible

Source URL: https://www.us.sandoz.com/our-work/biosimilars/biosimilars-and-access-treatment

Links

[1] https://www.us.sandoz.com/our-work/biosimilars/biosimilars-and-access-treatment
[2] https://www.us.sandoz.com/our-work/biosimilars/biosimilar-development-process
[3] https://www.iqvia.com/institute/reports/medicine-use-and-spending-in-the-us-review-of-2017-outlook-to-2022
[4] http://biosimilarscouncil.org/wp-content/uploads/2019/03/Biosimilars-Council-Patient-Access-Study.pdf
[5] https://www.drugchannels.net/2020/10/the-booming-biosimilar-market-of-2020.html?m=1
[6] https://www.census.gov/prod/2014pubs/p25-1140.pdf
[7] https://www.rand.org/pubs/perspectives/PE264.html
[8] https://wayback.archive
[9] http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm